Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab + Bempegaldesleukin in Solid Tumors
NCT04052204Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Dec 2019
- Primary completion
- Sep 2020
- Modality
- Cytokines & Interferons
- Countries
- 4
01
Overview
A Phase 2 trial of bempegaldesleukin in squamous cell carcinoma of the head and neck (HNSCC), metastatic castration-resistant prostate cancer (mCRPC), sponsored by Pfizer. Started Dec 2019; status: terminated.
02
Drugs
bempegaldesleukin
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04052204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04052204.